Allergy and autoimmune biotech company Lycia Therapeutics (LYCA.US) is set to list on Nasdaq tonight! IPO priced at $18 per share, aiming to raise $317.5 million.

Zhito Finance APP has learned that Lycia Therapeutics, a biotech company focused on the treatment of allergic and autoimmune diseases, has expanded the size of its upcoming initial public offering (IPO) in the United States. According to a statement released by the company on Thursday, Lycia will offer 17.64 million shares at $18 per share to raise $317.5 million. A previous filing showed that the biotech company had originally planned to offer 14.7 million shares at a price of $16 to $18 per share.